Polatuzumab Vedotin in a Patient with Refractory Burkitt Lymphoma, a Case Report

被引：1

作者：

Alanzi, Meshaal ^{[5
,6
]}

Abu-Tineh, Mohammad ^{[1
]}

Szabados, Lajos ^{[2
]}

Eldean, M. Z. Sharaf ^{[3
]}

Alatasi, Sali ^{[3
]}

Taha, Ruba Y. ^{[1
]}

Elkourashy, Sarah A. ^{[1
,4
]}

机构：

[1] Hamad Med Corp, Dept Internal Med, Doha, Qatar

[2] Natl Ctr Canc Care & Res, Dept Med Oncol Hematol, Doha, Qatar

[3] Natl Ctr Canc Care & Res, Hamad Med Corp, Dept Nucl Med, Doha, Qatar

[4] Hamad Med Corp, Dept Pathol, Doha, Qatar

[5] Weill Cornell Med Univ, Doha, Qatar

[6] Hamad Med Corp, Internal Med Resident, Al Rayan Rd, Doha, Qatar

来源：

ONCOTARGETS AND THERAPY | 2023年 / 16卷

关键词：

Burkitt?s lymphoma; polatuzumab; Lymphoma; anti CD79b; resistant lymphoma;

D O I：

10.2147/OTT.S394193

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 ; 0836 ; 090102 ; 100705 ;

摘要：

Although Burkitt lymphoma is considered a curable disease due to the progress made in choosing the most effective first -line therapy, relapsed or refractory Burkitt lymphoma (BL) has a very poor outcome. There is a lack of data supporting the treatment regimens. We report a 48-year-old male with stage II Burkitt's lymphoma with no response to the first line of high-intensity chemotherapy. However, treatment with polatuzumab vedotin led to complete clinical remission for more than one year.

引用

页码：133 / 139

页数：7

共 21 条

[1] Approved indication: B-cell lymphoma
不详
[J]. AUSTRALIAN PRESCRIBER, 2020, 43 (06) : 218 - 219
[2] Translocations involving c-myc and c-myc function
Boxer, LM
Dang, CV
[J]. ONCOGENE, 2001, 20 (40) : 5595 - 5610
[3] Denis Burkitt and his contribution to haematology/oncology
Coakley, Davis
[J]. BRITISH JOURNAL OF HAEMATOLOGY, 2006, 135 (01) : 17 - 25
[4] Crombie Jennifer, 2021, Blood, V137, P743, DOI 10.1182/blood.2019004099
[5] Outcomes of HIV-associated Burkitt Lymphoma in Brazil: High treatment toxicity and refractoriness rates - A multicenter cohort study
da Silva, Wellington F.
Marques Garibaldi, Pedro Manoel
da Rosa, Lidiane Ines
Bellesso, Marcelo
Cle, Diego Villa
Delamain, Marcia Torresan
Rego, Eduardo Magalhaes
Pereira, Juliana
Rocha, Vanderson
[J]. LEUKEMIA RESEARCH, 2020, 89
[6] Polatuzumab Vedotin Plus Obinutuzumab and Lenalidomide in Patients With Relapsed/Refractory Follicular Lymphoma: Primary Analysis of the Full Efficacy Population in a Phase Ib/II Trial
Diefenbach, Catherine
Kahl, Brad S.
Banerjee, Lalita
McMillan, Andrew K.
Miall, Fiona
Briones, Javier
Cordoba, Raul
Hirata, Jamie
Chang, YiMeng
Musick, Lisa
Abrisqueta, Pau
[J]. BLOOD, 2019, 134
[7] Therapeutic potential of an anti-CD79b antibody-drug conjugate, anti-CD79b-vc-MMAE, for the treatment of non-Hodgkin lymphoma
Dornan, David
Bennett, Fiona
Chen, Yvonne
Dennis, Mark
Eaton, Dan
Elkins, Kristi
French, Dorothy
Go, Mary Ann T.
Jack, Andrew
Junutula, Jagath R.
Koeppen, Hartmut
Lau, Jeffrey
McBride, Jacqueline
Rawstron, Andy
Shi, Xiaoyan
Yu, Nancy
Yu, Shang-Fan
Yue, Peng
Zheng, Bing
Ebens, Allen
Polson, Andrew G.
[J]. BLOOD, 2009, 114 (13) : 2721 - 2729
[8] FDA, 2019, FDA APPR POL VED PII
[9] Novel Biological Insights and New Developments in Management of Burkitt Lymphoma and High-Grade B-Cell Lymphoma
Lap, Coen J.
Nassereddine, Samah
Dunleavy, Kieron
[J]. CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2021, 22 (07)
[10] Evaluation and use of an anti-cynomolgus monkey CD79b surrogate antibody-drug conjugate to enable clinical development of polatuzumab vedotin
Li, Dongwei
Lee, Donna
Dere, Randall C.
Zheng, Bing
Yu, Shang-Fan
Fuh, Franklin K.
Kozak, Katherine R.
Chung, Shan
Yadav, Daniela Bumbaca
Nazzal, Denise
Danilenko, Dimitry
Go, Mary Ann T.
Williams, Marna
Polson, Andrew G.
Poon, Kirsten Achilles
Prabhu, Saileta
[J]. BRITISH JOURNAL OF PHARMACOLOGY, 2019, 176 (19) : 3805 - 3818

← 1 2 3 →